公开(公告)号：US20210205208A1

公开(公告)日：2021-07-08

申请号：US17179053

申请日：2021-02-18

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David BARNHART ,  Michael Clinton KOONS ,  Madhu Sudan HARIHARAN ,  Jordan DUBOW ,  Thierry BILBAULT ,  Anthony John GIOVINAZZO

IPC: A61K9/00 ,  A61K47/02 ,  A61K31/473 ,  A61K47/14 ,  A61K47/26 ,  A61K9/70 ,  A61K47/36 ,  A61K45/06 ,  A61P25/16 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

公开(公告)号：US20200069571A1

公开(公告)日：2020-03-05

申请号：US16564864

申请日：2019-09-09

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David BARNHART ,  Michael Clinton KOONS ,  Madhu Sudan HARIHARAN ,  Jordan DUBOW ,  Thierry BILBAULT ,  Anthony John GIOVINAZZO

IPC: A61K9/00 ,  A61K47/02 ,  A61K31/473 ,  A61K47/14 ,  A61K47/26 ,  A61K9/70 ,  A61P25/16 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38 ,  A61K47/36 ,  A61K45/06

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

公开(公告)号：US20180133146A1

公开(公告)日：2018-05-17

申请号：US15789528

申请日：2017-10-20

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David BARNHART ,  Michael Clinton Koons ,  Madhu Sudan Hariharan ,  Jordan Dubow ,  Thierry Bilbault ,  Anthony John Giovinazzo

IPC: A61K9/00 ,  A61P25/16 ,  A61K31/473 ,  A61K9/70 ,  A61K47/10 ,  A61K47/14 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26 ,  A61K47/38

CPC classification number: A61K9/006 ,  A61K9/7007 ,  A61K31/473 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/183 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61P25/16

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.